Related Experiment Video
Updated: May 15, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death
P K Singha1, S Pandeswara, M A Venkatachalam
1Department of Pathology, UT Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Abstract:
Therapy resistance can be attributed to acquisition of anti-apoptotic mechanisms by the cancer cells. Therefore, developing approaches that trigger non-apoptotic cell death in cancer cells to compensate for apoptosis resistance will help to treat cancer effectively. Triple-negative breast cancers (TNBC) are among the most aggressive and therapy resistant to breast tumors. Here we report that manumycin A (Man A), an inhibitor of farnesyl protein transferase, reduces cancer cell viability through induction of non-apoptotic, non-autophagic cytoplasmic vacuolation death in TNBC cells. Man A persistently induced cytoplasmic vacuolation and cell death through the expression of microtubule-associated protein 1 light chain 3 (LC3) and p62 proteins along with endoplasmic reticulum (ER) stress markers, Bip and CHOP, and accumulation of ubiquitinated proteins. As inhibitors of apoptosis and autophagy failed to block cytoplasmic vacuolation and its associated protein expression or cell death, it appears that these processes are not involved in the death induced by Man A. Ability of thiol antioxidant, NAC in blocking Man A-induced vacuolation, death and its related protein expression suggests that sulfhydryl homeostasis may be the target of Man A. Surprisingly, normal human mammary epithelial cells failed to undergo cytoplasmic vacuolation and cell death, and grew normally in presence of Man A. In conjunction with its in vitro effects, Man A also reduced tumor burden in vivo in xenograft models that showed extensive cytoplasmic vacuoles and condensed nuclei with remarkable increase in the vacuolation-associated protein expression together with increase of p21, p27, PTEN and decrease of pAkt. Interestingly, Man A-mediated upregulation of p21, p27 and PTEN and downregulation of pAkt and tumor growth suppression were also mimicked by LC3 knockdown in MDA-MB-231 cells. Overall, these results suggest novel therapeutic actions by Man A through the induction of non-apoptotic and non-autophagic cytoplasmic vacuolation death by probably affecting ER stress, LC3 and p62 pathways in TNBC but not in normal mammary epithelial cells.
Insights
Manumycin A induces non-apoptotic cell death in triple-negative breast cancer (TNBC) by causing cytoplasmic vacuolation. This novel therapeutic approach targets cancer cells while sparing normal cells, offering a promising strategy for aggressive TNBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Therapy resistance in cancer, particularly triple-negative breast cancer (TNBC), is often linked to anti-apoptotic mechanisms.
- Developing therapeutic strategies that induce non-apoptotic cell death is crucial for overcoming apoptosis resistance in aggressive cancers.
Purpose of the Study:
- To investigate the effects of manumycin A (Man A), a farnesyl protein transferase inhibitor, on TNBC cell viability and death.
- To elucidate the mechanism of Man A-induced cell death, focusing on its non-apoptotic and non-autophagic nature.
Main Methods:
- Treatment of TNBC cells and normal mammary epithelial cells with Man A.
- Analysis of cell viability, cytoplasmic vacuolation, and expression of key proteins including LC3, p62, ER stress markers (Bip, CHOP), p21, p27, PTEN, and pAkt.
- In vivo studies using xenograft models to assess Man A's effect on tumor burden.
- LC3 knockdown experiments in MDA-MB-231 cells.
Main Results:
- Man A reduced TNBC cell viability by inducing non-apoptotic, non-autophagic cytoplasmic vacuolation death.
- This process involved endoplasmic reticulum (ER) stress, LC3 and p62 pathways, and accumulation of ubiquitinated proteins, independent of apoptosis and autophagy inhibitors.
- Man A selectively targeted TNBC cells, sparing normal mammary epithelial cells, and reduced tumor burden in vivo.
- Man A-induced effects, including tumor growth suppression and modulation of specific protein expressions, were mimicked by LC3 knockdown.
Conclusions:
- Manumycin A represents a novel therapeutic agent for TNBC, inducing a unique form of cell death characterized by cytoplasmic vacuolation.
- The mechanism likely involves ER stress and LC3/p62 pathways, with potential targeting of sulfhydryl homeostasis.
- Man A demonstrates significant therapeutic potential due to its efficacy against TNBC and selectivity over normal cells.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
